Vext Science Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Vext Science is forecast to grow earnings and revenue by 111.1% and 34.6% per annum respectively while EPS is expected to grow by 103.3% per annum.
Wichtige Informationen
111.1%
Wachstumsrate der Gewinne
103.3%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 18.0% |
| Wachstumsrate der Einnahmen | 34.6% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 29 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Keine Aktualisierungen
Recent updates
Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 103 | 17 | 11 | N/A | 1 |
| 12/31/2025 | 58 | 10 | 8 | 7 | 3 |
| 12/31/2024 | 37 | -1 | 6 | -1 | 4 |
| 6/30/2024 | 33 | -7 | -1 | 0 | N/A |
| 3/31/2024 | 34 | -2 | 2 | 4 | N/A |
| 12/31/2023 | 35 | 4 | 2 | 4 | N/A |
| 9/30/2023 | 35 | 5 | 4 | 6 | N/A |
| 6/30/2023 | 34 | 7 | 0 | 5 | N/A |
| 3/31/2023 | 34 | 9 | -2 | 3 | N/A |
| 12/31/2022 | 35 | 11 | -3 | 6 | N/A |
| 9/30/2022 | 37 | 6 | -3 | 8 | N/A |
| 6/30/2022 | 38 | 6 | 0 | 11 | N/A |
| 3/31/2022 | 39 | 6 | -10 | 12 | N/A |
| 12/31/2021 | 37 | 5 | -8 | 11 | N/A |
| 9/30/2021 | 34 | 5 | -9 | 8 | N/A |
| 6/30/2021 | 33 | 5 | -8 | 8 | N/A |
| 3/31/2021 | 30 | 4 | 2 | 6 | N/A |
| 12/31/2020 | 25 | 2 | -1 | 3 | N/A |
| 9/30/2020 | 22 | 0 | -2 | 2 | N/A |
| 6/30/2020 | 20 | 0 | -6 | 1 | N/A |
| 3/31/2020 | 20 | 0 | -6 | 0 | N/A |
| 12/31/2019 | 22 | 3 | -6 | 0 | N/A |
| 9/30/2019 | 23 | 4 | -5 | -1 | N/A |
| 6/30/2019 | 23 | 5 | -3 | -1 | N/A |
| 3/31/2019 | 21 | 4 | -1 | 0 | N/A |
| 12/31/2018 | 18 | 4 | 1 | 2 | N/A |
| 12/31/2017 | 15 | 4 | N/A | 2 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: VV5 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).
Ertrag vs. Markt: VV5 is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hohe Wachstumserträge: VV5 is expected to become profitable in the next 3 years.
Einnahmen vs. Markt: VV5's revenue (34.6% per year) is forecast to grow faster than the German market (5.5% per year).
Hohe Wachstumseinnahmen: VV5's revenue (34.6% per year) is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Insufficient data to determine if VV5's Return on Equity is forecast to be high in 3 years time